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Abstract 
The appropriate use of pre-exposure prophylaxis (PrEP) by men who have sex with 
men (MSM) can be highly effective at reducing HIV transmission. Our review 
examined prevalence estimates, sexual behaviors, and medication adherence 
among MSM PrEP users in high-income countries. Papers published between 
January 2008 and December 2018 were identified through Medline, Web of Science, 
CINAHL, and Central. The search identified 643 publications, of which 52 were 
included in the final synthesis. We found that PrEP initiation was not consistently 
associated with significant changes in sexual behavior, but some users may have 
risk compensated. A minority of MSM used PrEP and they had high levels of 
adherence. PrEP-related stigma, side effects, and psychosocial factors lead to non-
adherence. A daily routine, pill boxes, alarms/texts, and education can promote 
adherence. Further research is required to examine PrEP impact on sexual behavior 
and factors that influence adherence in high-risk MSM sub-populations.    
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Pre-exposure prophylaxis use and medication adherence among men 
who have sex with men: A systematic review of the literature 
 
In 2016, there were more than 26,000 new HIV diagnoses in Western Europe; 
in the United States there were more than 38,000 new HIV diagnoses 
(Centers for Disease Control and Prevention [CDC], 2017; European Centre for 
Disease Prevention and Control, 2017). Men who have sex with men (MSM) are a 
minority in the populations of the United States and Western Europe but are at 
higher risk of HIV transmission compared to the general population. In Western 
Europe, MSM accounted for 45% of new HIV diagnoses and, in the United States, 
MSM accounted for 67% of new HIV diagnoses (CDC, 2017; European Centre for 
Disease Prevention and Control, 2017). The development of effective pre-exposure 
prophylaxis (PrEP) is an important HIV prevention strategy for MSM.  
In 2012, the U.S. Food and Drug Administration was the first to approve PrEP 
for high-risk groups (CDC, 2014). In 2014, the United States published guidelines 
recommending that PrEP be provided to uninfected MSM who were not in a mutually 
monogamous relationship and had either had condomless anal intercourse (CAI) or 
been diagnosed with a sexually transmitted infection (STI) in the previous 6 months 
(CDC, 2014). In 2015, France implemented PrEP through the national health care 
system, and in 2016, the European Medicines Agency provided authorization for 
PrEP use in European Union countries (Eurosurveillance, 2018). Since that time, a 
few European countries have implemented PrEP through their national health care 
systems (Eurosurvelliance, 2018).  
Since the introduction of PrEP, concern has been raised about risk 
compensation or changes in levels of high-risk sexual behavior because of PrEP 
(Blumenthal & Haubrick, 2014). The key public health concern following PrEP 
initiation has been related to a potential increase in STIs (Blumenthal & Haubrick, 
2014). Proxy measures such as changes in sexual behavior are often used in 
research, but the public health focus must be on any increase in STIs.    
PrEP effectiveness and efficiency in reducing HIV in MSM will depend on 
uptake and adherence for those at highest risk. To date, there has been no 
comprehensive systematic review to synthesize what is known about prevalence of 
PrEP use, sexual behaviors, and biopsychosocial factors associated with PrEP 
adherence in MSM. We examined biopsychosocial factors associated with PrEP that 
have influenced medication adherence by MSM in high-income countries. Our 
objectives were:  
1. To define prevalence estimates for PrEP use in MSM; 
2. To identify factors associated with PrEP use, including socio-
demographics and reasons/motivators for PrEP initiation;  
3. To describe high-risk sexual behaviors and STI rates in PrEP users; 
4. To identify levels of adherence in episodic and continuous dosing 
regimens; and 
5. To describe the biopsychosocial factors that influence PrEP medication 




Our systematic review was conducted and reported in accordance with the 
Preferred Items for Systematic Reviews and Meta-Analysis (PRISMA; Liberati et al., 
2009). Four databases (Medline, CINAHL, Web of Science, CENTRAL) were used 
because they included medical, nursing, allied health professional, sociological, and 
clinical trial journals. Search terms were generated based on the population (men 
who have sex with men, homosexual men, gay men, gay males), intervention (pre-
exposure prophylaxis, PrEP), and outcomes of interest (adherence, non-adherence, 
concordance, compliance). All possible combinations of MeSH terms, MeSH 




We included research that (a) examined actual use (as opposed to intended 
use) of PrEP; (b) had a sample of uninfected MSM; (c) were from high-income 
countries as defined by The World Bank (2019); (d) were primary research, fully 
published in peer reviewed journals; (e) had cross sectional, cohort, case control, 
qualitative, or randomized controlled trial (RCT) designs; and (f) were published in 
English from January 2008 through December 2017. 
 
Ethical Considerations 
As per the institutional ethics guidelines, ethics approval was not required as 
this was a review of peer reviewed published literature.     
Study Selection and Data Extraction 
One reviewer conducted the search using a predefined protocol developed 
with two senior researchers. Data retrieved through the search were extracted into 
Endnote x8 (Thomson Reuters, New York, USA). At the abstract stage, an 
independent reviewer examined a random sample of abstracts (10% of excluded and 
20% of included articles) to ensure robustness of inclusion and exclusion criteria. All 
differences were discussed and resolved. Data from the articles included in the final 
syntheses were extracted by one reviewer into a structured template.  
 
Data Analysis 
We synthesized evidence from studies that used a range of research methods 
and had wide variances in exposures/outcomes. A four-stage framework and 
techniques were used to increase transparency and trustworthiness of the narrative 
synthesis (Popay et al., 2006), and to compare and synthesize evidence in the 
review. The Antecedent, Behavior, and Consequence (ABC) framework was used to 
(a) understand predictors that may have occurred before an event (antecedents), (b) 
describe the process involved in an event (behavior), and (c) determine what factors 
might be outcomes of the event (consequences; Meaden, Ayvazo, & Ostrosky, 
2014). Table 1 contains a provisional ABC analysis of PrEP use drawn from the 
literature and research team discussions.  
 
Quality Assessment 
Three validated tools were chosen to appraise the quality of studies included 
in the review’s final synthesis: (a) the National Heart, Lung and Blood Institute 
(NHLBI, 2019) tool assessed cohort/cross sectional studies, (b) the Effective Public 
Health Practice Project (2019) tool assessed RCTs/controlled clinical trials, and (c) 
the Critical Appraisal Skills Programme (2019) qualitative checklist assessed 
qualitative studies. All three also assessed clarity and rigor of outcomes/measures, 





The number of studies identified, reviewed, selected, and reasons for 
exclusion are summarized in Figure 1. The initial number of articles captured from 
the search was 1,071; 52 articles were included in the final review.  
 
Study Characteristics  
Table 2 provides a summary of the aim, population, country, sample size, 
year of data collection, study design, appropriate overall quality rating, and ABC 
findings of the 52 articles included in the review. Figure 2 provides a summary of our 
main findings, which is structured using the ABC framework. The majority of the 
studies were from the United States (44); other studies were from Canada/France 
(3), Switzerland (1), France (1), United Kingdom (1), Canada (1), and Australia (1). 
The majority were cross sectional (25) or cohort (12) in design; the remaining studies 
were qualitative (9) or RCTs (6).  
 
Study Quality  
The majority of the cross-sectional studies had a fair quality rating, which, on 
the NHLBI tool means that a study could be susceptible to bias, but the findings were 
relevant; strengths and weaknesses were specific to each paper (NHLBI, 2019).  
Most reports did not provide sample size justification, measured exposures only 
once, and were unclear if researchers were blinded to the status of the sample. The 
primary strengths in most studies were clear objectives, defined exposures and 
outcomes, and appropriate methods for data analysis.  
Most of the cohort studies were rated as good in quality, which is the best 
NHLBI quality rating and means studies have a minimal level of bias and the findings 
are valid (NHLBI, 2019). The key strengths of the cohort studies were analysis of 
different exposure levels and exposures were measured more than once. Limitations 
in most of the cohort studies were the lack of sample size justification and not being 
clear if researchers were blinded to the sample status.  
The Critical Appraisal Skills Programme qualitative tool does not provide an 
overall quality level of rating. However, the majority of qualitative studies provided a 
clear recruitment strategy, justified data collection methods, had ethics approval, 
described a rigorous analysis method, and provided findings in a clearly structured 
format. Most did not examine wider ethical issues raised in or from the study.  
Most of the RCTs were rated as moderate in quality, which means studies 
have a robust and valid design, but a component in the study design had limitations 
(Effective Public Health Practice Project, 2019). The primary strengths of these 
studies were clear methods of randomization, no differences in study groups, sample 
blinded to the study outcome, and sample retention greater than 80%. Most were 
limited by not describing the reliability and validity of study assessment tools. 
 
Prevalence of PrEP Use 
Twenty studies from the United States (17), France (1), Australia (1), and 
Switzerland (1) examined prevalence estimates of PrEP use by MSM. Sample sizes 
ranged from 157 to 6,483 and all were cross sectional in design. The sample was 
heterogenous, as studies examined a variety of MSM populations using different 
recruitment techniques, with varied attempts to ensure representativeness. For 
example, some studies specifically recruited young MSM (YMSM) or minority 
racial/ethnic MSM, and the location of recruitment in some studies was primarily at 
gay-centric venues. PrEP prevalence estimates ranged from 0% in a U.S. study 
conducted in 2004, to 12% in a U.S. study conducted in 2014 (Chen, Snowden, 
McFarland, & Raymond, 2016; Goedel, Halkitis, Greene, Hickson, & Duncan, 2016).  
Five U.S. studies collected data prior to 2012 and reported a PrEP prevalence 
estimate range of 0% to 1.5% (Chen et al., 2016; Hood et al., 2016; Liu et al., 2008; 
Patrick et al., 2017; Rucinski et al., 2013). Fourteen U.S. studies conducted during or 
after 2012 identified a prevalence range of 1.5% to 12%, although the majority of the 
higher estimates (9%-12%) came from five studies that collected data in 2015 
(Bauermeister, Meanley, Pingel, Soler, & Harper, 2014; Eaton et al., 2017; Goedel, 
Halkitis, Greene, & Duncan, 2016; Goedel, Halkitis, Greene, Hickson et al., 2016; 
Gupta, Lounsbury, & Patel, 2017; Holloway et al., 2017; Hoots, Finlayson, Nerlander, 
& Paz-Bailey, 2016; Klevens et al., 2017; Kuhns, Hotton, Schneider, Garofalo, & 
Fujimoto, 2017; Mayer et al., 2016; Oldenburg et al., 2016; Snowden, Chen, 
McFarland, & Raymond, 2017; Strauss et al., 2017). The highest estimate of 
approximately 12% from two studies included one small sample recruited via an 
MSM geo-social networking application and the other was a sample of YMSM (< 30 
years of age; Goedel, Halkitis, Greene, Hickson et al., 2016; Kuhns et al., 2017). 
With the exception of these studies, the 2015 estimated range of PrEP prevalence 
was approximately 9% to 10%. It appeared that MSM samples reported increasing 
use of PrEP following U.S. approval of PrEP in 2012 and guidelines for high-risk 
groups in 2014.    
Studies from France, Australia, and Switzerland reported a prevalence 
estimate range of 2% to 5% (Castro et al., 2017; Hampel et al., 2017; Zablotska et 
al., 2013). Data collection dates in these studies ranged from 2011 to 2017, but the 
two more recent studies (2014-2017) from Western Europe reported a range of 4% 
to 5% (Castro et al., 2017; Hampel et al., 2017). The Australian study in 2011 found 
that 2.5% of the MSM sample were using PrEP (Zablotska et al., 2013). However, 
this study may not be generalizable to wider MSM populations as it recruited men 
from gay venues/events and sexual health clinics. Due to limited evidence, it was not 
possible to determine the precise prevalence of PrEP use amongst MSM outside of 
the United States.  
 
Socio-Demographics of MSM PrEP Users 
Twenty-seven studies reported or examined key socio-demographics of MSM 
who were using or had previously used PrEP. The majority were U.S. studies, which 
consisted of different designs: cross section to RCT. Sixteen studies did not recruit 
samples of a specific age and reported a median or mean age of PrEP users from 27 
to 42 years (Arnold et al., 2017; Chan, Glynn, et al., 2016; Chan, Mena, et al., 2016; 
Collins, McMahan, & Stekler, 2017; Gilmore et al., 2013; Gupta et al., 2017; Hojilla et 
al., 2016; Marcus et al., 2016; Mayer et al., 2017; McCormack et al., 2016; Molina et 
al., 2015; Montgomery et al., 2016; Oldenburg et al., 2017; Parker et al., 2015; 
Storholm, Volk, Marcus, Silverberg, & Satre, 2017; Volk et al., 2015).  
 Three studies reported that no age was significantly associated with PrEP 
use (Hoots et al., 2016; Strauss et al., 2017; Zablotska et al., 2013), but, two U.S. 
studies identified PrEP use as more common in older men (Doblecki-Lewis et al., 
2017; Snowden et al., 2017). These two studies may be limited in generalizability to 
the PrEP-using population as they had relatively small samples. From the evidence, 
PrEP use peaked in the late 20s to early 40s but was used across all ages.    
Nineteen studies provided a breakdown of race/ethnicity; 13 of these studies 
reported that most participants were White (Chan, Glynn, et al., 2016; Chan, Mena, 
et al., 2016; Collins et al., 2017; Doblecki-Lewis et al., 2017; Gilmore et al., 2013; 
Hojilla et al., 2016; Kuhns et al., 2017; Marcus et al., 2016; Mayer et al., 2017; 
McCormack et al., 2016; Montgomery et al., 2016; Oldenburg et al., 2017; Parker et 
al., 2015). Two U.S. studies reported that Whites were more likely to use PrEP 
compared to other races/ethnic groups (Hoots et al., 2016; Snowden et al., 2017). A 
study from the United States identified Black race as negatively associated with 
PrEP use (Kuhns et al., 2017), although this study only focused on YMSM. In 
contrast, an Australian study reported that minority racial/ethnic groups were more 
likely to use PrEP than Whites (Zablotska et al., 2013) and another U.S. study of 
YMSM reported that race/ethnicity was not associated with PrEP use (Strauss et al., 
2017). In comparison, Strauss et al. (2017) had a sample size of 759 and Zablotska 
et al. (2013) had a sample size of 3,677. Overall, population representative evidence 
base was limited, and it was not possible to determine if there was an association 
between race/ethnicity and PrEP use.   
 
Reasons and Motivators for PrEP Initiation 
Twelve studies examined MSM reasons for starting PrEP. One study was an 
RCT and the primary reason for being involved in the study was to provide 
something meaningful back to the community (Gilmore et al., 2013). As this study 
was a trial, it may not help to understand key motivators for PrEP use. Three studies 
found that people started PrEP because they had or would be having multiple sex 
partners (Arnold et al., 2017; Holloway et al., 2017; Strauss et al., 2017) and four 
studies reported that a motivator for some MSM was that they had previously had or 
would have sex with partners whose HIV status was unknown or positive (Chan, 
Glynn, et al., 2016; Holloway et al., 2017; Kuhns et al., 2017; Strauss et al., 2017). 
Two studies found that a history of having CAI or inconsistent condom use was 
associated with PrEP uptake (Collins et al., 2017; Kuhns et al., 2017); another study 
found that some men used PrEP because it allowed them to not use condoms 
(Taylor et al., 2014).  
Five studies found that a central motivator for starting PrEP was to remove 
the anxiety of contracting HIV (Hojilla et al., 2016; Holloway et al., 2017; Hosek et al., 
2013; Malone et al., 2017; Mimiaga, Closson, Kothary, & Mitty, 2014), but one U.S. 
study found no factors significantly associated with initiating PrEP (Chan, Mena, et 
al., 2016). The evidence suggests that planned high-risk sexual behaviors and 
removing anxiety related to contracting HIV motivated MSM to start PrEP.  
 
Sexual Behavior  
Twenty-seven articles, the majority of which were from the United States, 
examined aspects of high-risk sexual behavior. Eight studies reported CAI rates for 
PrEP users (27% - 87%; Castro et al., 2017; Gilmore et al., 2013; Goedel, Halkitis, 
Greene, & Duncan, 2016; Gupta et al., 2017; Holloway et al., 2017; Hosek et al., 
2017; Parker et al., 2015; Storholm et al., 2017). The lowest rate (27%) was in a 
study where the majority of participants had a main partner (Castro et al., 2017); with 
the exception of this study, the CAI range was 40% to 87%.  
Five studies, which examined changes in CAI behavior after participants had 
started PrEP, reported no increase in rates of CAI or changes in condom use (Hojilla 
et al., 2016; Hosek et al., 2013; Liu et al., 2013; Molina et al., 2015; Parker et al., 
2015). However, three studies (2 RCTs, 1 open label) reported increases in the 
frequency of CAI and, in two studies, CAI was specifically receptive (McCormack et 
al., 2016; Molina et al., in press; Oldenburg et al., 2017). McCormack et al. (2016) 
found that the increase in receptive CAI occurred only in participants who reported 
more than 10 sexual partners. However, six studies that examined PrEP use over 
different time frames reported that PrEP initiation did not lead to an increased 
number of sex partners for the majority of participants (McCormack et al., 2016; 
Molina et al., 2015; Molina et al., in press; Oldenburg et al., 2017; Parker et al., 
2015; Volk et al., 2015). Two U.S. studies found that, following PrEP initiation, 35% 
to 41% of the sample decreased use of condoms, whilst 3% to 27% reported 
increased use of condoms (Strauss et al., 2017; Volk et al., 2015).  
Four studies reported that PrEP users were more likely to have more sex 
partners than non-PrEP users (Goedel, Halkitis, Greene, & Duncan 2016; Goedel, 
Halkitis, Greene, Hickson et al., 2016; Holloway et al., 2017; Okafor, Gorbach, 
Ragsdale, Quinn, & Shoptaw, 2017). Four studies found that PrEP users were more 
likely to have sex with partners living with HIV than non-PrEP users (Holloway et al., 
2017; Kuhns et al., 2017; Okafor et al., 2017; Taylor et al., 2014). One U.S. study 
reported that MSM who engaged in CAI with partners living with HIV were five times 
more likely to use PrEP than MSM who did not have CAI with men living with HIV 
(Hoots et al., 2016).  
The evidence for risk compensation (increases in high-risk sexual behaviors) 
and number of sexual partners after starting PrEP was mixed. The evidence did 
indicate that PrEP users may have had more CAI and sex partners than non-PrEP 
users, including men living with HIV. However, this was expected as CAI and partner 
numbers were criteria for being offered PrEP.  
 
Sexually Transmitted Infections 
Fourteen studies reviewed STIs in MSM who used PrEP. Nine studies 
reported an overall STI incidence estimate for PrEP users, which ranged from 20% 
to 66% (Bien, Patel, Blackstock, & Felsen, 2017; Chan, Mena, et al., 2016; Doblecki-
Lewis et al., 2017; Hosek et al., 2017; Liu et al., 2016; Marcus et al., 2016; 
McCormack et al., 2016; Molina et al., 2015; Volk et al., 2015). The lowest rate 
(20%) was from a U.S. study with a relatively small number of PrEP users and 66% 
was from a study of YMSM. Only six studies examined specific STIs, and the 
majority identified the most common infections as chlamydia and gonorrhea 
(Daughtridge, Conyngham, Ramirez, & Koenig, 2015; Deutsch et al., 2015; Hosek et 
al., 2013; McCormack et al., 2016; Molina et al., 2015; Molina et al., in press; Volk et 
al., 2015). The wide range of STI incidence reflected heterogeneity of study 
populations, but all found a high STI burden in MSM at high risk of HIV acquisition.  
Hoots et al. (2016) found that MSM who had been diagnosed with an STI in 
the previous year were more likely to use PrEP than MSM who had not had an STI in 
the previous year, but this finding should be expected, as an STI in the previous year 
was a clinical indicator for PrEP. Another U.S. study reported that STI diagnosis in 
the previous year was associated with PrEP use (Holloway et al., 2017). A U.S. 
cohort study reported that, 1 year after PrEP initiation, diagnosis of urethral 
gonorrhea and rectal chlamydia increased, but all other STIs/sites remained stable 
(Marcus et al., 2016). Another U.S. cohort study reported that, following PrEP 
initiation, overall STI incidence at 6 months was 30% and increased to 50% at 12 
months (Volk et al., 2015). Cohort studies were limited by not having control groups 
to determine if STI increases were directly related to PrEP use. In contrast, two 
RCTs, which analyzed the efficacy of PrEP, reported that, during study follow-up, 
PrEP and control groups showed no significant differences in STI rates (McCormack 
et al., 2016; Molina et al., 2015). The evidence suggests that MSM using PrEP had a 
high burden of other STIs, but there was limited evidence to suggest that PrEP use 
increased or reduced STI incidence.  
 
PrEP Adherence  
Eleven studies examined levels of PrEP adherence, using single- or 
combined-monitoring methods, ranging from self-report to blood tests. Ten studies 
examined continuous dosing regimens, in which adherence was defined as taking 
four or more pills per week. Four studies monitored PrEP levels via blood tests and 
reported that, 24 weeks after staring PrEP, 20% to 84% of the sample had drug 
levels equivalent to 4 or more pills per week (Hosek et al., 2017; Hosek et al., 2013; 
Liu et al., 2016; Mayer et al., 2017). Two of these studies reported that, 48 weeks 
after starting PrEP, 34% to 80% of the sample had adequate drug levels (Hosek et 
al., 2015; Liu et al., 2016). The studies that reported lower adherence levels of 20% 
to 55% at week 24, and 34% at week 48, only examined PrEP use in YMSM (Hosek 
et al., 2015; Hosek et al., 2013). In contrast, the two studies that had non-specific 
age samples reported an adherence level at week 24 of more than 80% (Liu et al., 
2016; Mayer et al., 2017).  
Six studies used self-report to monitor PrEP use, in which three reported 
overall adherence of 80% to 90% (Chan, Mena, et al., 2016; Daughtridge et al., 
2015; Liu et al., 2016). A study that examined potential and actual use of PrEP in the 
cycle of change found that 98% of the sample using PrEP reported taking more than 
four doses per week (Parsons et al., 2017). Two studies reported that, at 6 months of 
PrEP use, participants reported taking 20 to 27 daily doses in the previous 30 days 
(Hosek et al., 2013; Montgomery et al., 2016). In contrast, Storholm et al. (2017) 
reported that, after using PrEP for 3 months, their sample had taken 5.5 doses a 
week on average. Three studies used pill counting as a monitoring mechanism and 
reported an adherence level of 80% to 92% (Liu et al., 2016; Marcus et al., 2016; 
Mayer et al., 2017).  
Two studies used two or more monitoring strategies and found that an 
adherence level of more than 80% was consistent between self-report and blood 
testing (Liu et al., 2016; Mayer et al., 2017). However, Hosek et al. (2013) found that 
participants reported high adherence levels, but blood monitoring indicated that a 
small minority had adequate drug levels to evidence effective adherence. Studies 
showing consistent adherence had generalized MSM samples; inconsistent reporting 
was found in studies of YMSM, ages 18 to 22.  
Only three articles examined episodic PrEP dosing. Recommended dosing in 
these studies was two pills 2 to 24 hours before sex, a third pill 24 hours after the 
first dose, and a fourth pill 24 hours later. Two reported that about half fully adhered 
and a quarter partially adhered to the regimen (Molina et al., 2015; Molina et al., in 
press). Molina et al. (2015) reported that 28% of their sample used 15 pills per month 
on average. In contrast, Molina et al. (in press) reported that 70% of their sample 
had detectable drug levels 6 months after starting PrEP. Sagaon-Teyssier et al. 
(2016) found that 59% of their sample fully adhered to the dosing schedule; 41% 
used a sub-optimal dosing regimen. In contrast, Molina et al. (in press) reported that 
9% of their sample did not use PrEP consistently at their last sexual encounters.  
The majority of episodic PrEP users adhered to the regimen, but the evidence was 
not as strong as for continuous regimens. 
Fourteen studies examined biopsychosocial factors that could affect 
adherence; the majority of evidence came from continuous regimens. Six studies 
examined patient-related lifestyle factors. Two found that 27% to 47% of participants 
forgot to take pills because of busy schedules and 28% to 50% simply forgot to take 
some doses (Hosek et al., 2017; Hosek et al., 2013). Three studies reported that 
27% to 60% of participants didn’t take doses when away from home (Gilmore et al., 
2013; Hosek et al., 2017; Hosek et al., 2013). Three studies examined elements of 
substance use; two reported that alcohol use had a negative impact on PrEP 
adherence (Storholm et al., 2017; Taylor et al., 2014) and two reported that stimulant 
drugs were related to non-adherence (Oldenburg et al., 2016; Storholm et al., 2017).  
A study from Canada examined mental health and substance use in men 
being processed for initial PrEP consultation and reported problematic alcohol use 
(38%), problematic drug use (35%), and/or a mental health diagnosis (41%; Tan, 
Leon-Carlyle, Mills, Moses, & Carvalhal, 2016). One study reported that symptoms of 
depression in participants contributed to missed doses of PrEP (Taylor et al., 2014). 
In contrast, five studies stated that a fundamental reason to use PrEP was to remove 
the fear of contracting HIV (Hojilla et al., 2016; Holloway et al., 2017; Hosek et al., 
2013; Malone et al., 2017; Mimiaga et al., 2014). Overall, mixed factors were related 
to individual PrEP user adherence.    
Five studies examined social and economic factors and reported that 
participants had a fear of being stigmatized by social supports if they knew the 
participant was on PrEP (Arnold et al., 2017; Collins et al., 2017; Hosek et al., 2017; 
Storholm et al., 2017; Taylor et al., 2014). One study reported fear of being judged 
as promiscuous by community peers (Collins et al., 2017). Storholm et al. (2017) 
stated that 10% of their sample had experienced stigma from other gay men 
because of using PrEP. In contrast, Hosek et al. (2017) reported that only 2.5% of 
their sample had missed doses because they did not want others to know they were 
taking PrEP.  
Three U.S. studies reported that lack of affordable health care was a barrier 
for some men (Chan, Mena, et al., 2016; Doblecki-Lewis et al., 2017; Taylor et al., 
2014). Three studies reported that some of participants had reservations about 
discussing PrEP use with health care providers for fear of stigma associated with 
risky sexual behavior and HIV medication (Collins et al., 2017; Eaton et al., 2017; 
Taylor et al., 2014). The evidence indicated that fear of stigma from peers, health 
care providers, and health care barriers impacted PrEP uptake, but evidence was 
limited related to its influence on PrEP adherence.         
Five studies examined the impact of side effects on PrEP adherence. Three 
reported that up to 11% of their samples experienced side effects when taking PrEP 
(Liu et al., 2016; McCormack et al., 2016; Molina et al., in press). McCormack et al. 
(2016) reported that 8% of their sample missed doses due to side effects, most 
commonly nausea and headache. A U.S. study of YMSM reported that 4.5% of the 
sample intentionally missed doses to avoid side effects (Hosek et al., 2017). In 
contrast, Arnold et al. (2017), in a small sample, found a majority of participants had 
no side effects from PrEP and only 2 missed doses because of potential side effects. 
Overall, the evidence suggests that adherence was affected by side effects in a 
minority of PrEP users, but particularly in YMSM.  
Six studies examined factors that facilitated optimal adherence to PrEP. Three 
reported an established daily routine as one of the most effective facilitators for 
adherence (Gilmore et al., 2013; Parker et al., 2015; Taylor et al., 2014); two found 
that being on other medications facilitated daily doses of PrEP (Gilmore et al., 2013; 
Taylor et al., 2014). Six studies examined adherence prompts and props: three 
studies reported the use of prompts (e.g., daily texts, alarms) improved adherence 
(Parker et al., 2015; Storholm et al., 2017; Taylor et al., 2014) and three found that 
some PrEP users found pill boxes useful (Gilmore et al., 2013; Parker et al., 2015; 
Storholm et al., 2017), but Gilmore et al. (2013) also reported that some participants 
did not find pill boxes helpful.  
Sagaon-Teyssier et al. (2016) found that PrEP, in combination with other HIV 
prevention strategies, promoted adherence to dosing regimens, and Raifman et al. 
(2017) reported that a brief PrEP education intervention resulted in a 150% increase 
in PrEP use compared to PrEP awareness and previous PrEP use prior to 
education. Another facilitator was related by users who engaged in high-risk sexual 
behavior and viewed PrEP as a “necessity” to reduce HIV risk. The overall evidence 
did not indicate that one specific factor promoted optimal adherence, but adherence 
prompts, structured adherence support, and education might be beneficial.   
 
Discussion 
To our knowledge, this was the first systematic review to analyze MSM PrEP 
use and medication adherence in high-income countries. Other literature reviews 
(Huang et al., 2018; Pinto, Berringer, Melendez, & Mmeje, 2018; Sidebottom, 
Ekstrom, & Stromdahl, 2018; Traeger et al., 2018; Young & McDaid, 2014) examined 
PrEP efficacy, sexual behavior, and medication adherence, but did not provide in-
depth behavioral analyses of PrEP use among MSM.  
We used the ABC framework (Meaden et al., 2014) to structure and 
synthesize evidence of behavioral processes in MSM PrEP use. The main strength 
of this approach was that it allowed a wide range of complex evidence to be 
synthesized into a three-stage process. Sexual behavior was congruent with the 
three ABC stages. Men who initiated PrEP used it as an additional HIV risk reduction 
strategy and engaged in varied high-risk sexual behaviors (Antecedents). Following 
PrEP initiation, users were likely to continue high-risk sexual activity (Behaviors) in 
comparison to non-users. There was mixed evidence on whether PrEP initiation was 
substantially associated with risk compensation, but some MSM subgroups saw 
PrEP as an opportunity to reduce consistent condom use (Consequences).  
The evidence for changes in sexual behavior (risk compensation) following 
PrEP use is complex. As in a systematic review of PrEP efficacy (Huang et al., 
2018), we did not find consistent increases in sex partners or CAI and there was a 
lack of evidence to indicate an increase in STI diagnoses. However, another 
systematic review concluded that PrEP use was associated with increased sex 
without condoms and diagnoses of STIs, particularly a significant increase in rectal 
chlamydia (Traeger et al., 2018).  
Two studies in our review suggested that there were increases in higher risk 
behaviors in a subgroup of PrEP users. Overall, this reflected limitations in assessing 
changes in sexual behavior in observational studies. First, PrEP users were likely to 
engage in high-risk sexual activity prior to PrEP initiation and to continue those 
behaviors. Second, before and after observational studies cannot control for secular 
change and social desirability biases in reporting high-risk behaviors on or off PrEP. 
Further research is required to investigate if risk compensation and STI diagnosis 
are associated with PrEP uptake.   
We found that a minority (<10%) of MSM were using PrEP, but this was with 
limitations in non-representative samples with clear geographic heterogeneity in 
PrEP use and mixed quality. There was a lack of substantive data on the population 
level of MSM PrEP use in high-income countries and studies examining prevalence 
estimates were limited by heterogenous sampling.  
A systematic review of PrEP implementation in the United States found health 
care system barriers affecting uptake, including PrEP-related stigma and financial 
capability, which was non-equitable across races/ethnicities (Pinto et al., 2018).  This 
study was congruent with findings in our review, but we found challenges when 
engaging young and racial/ethnic minority MSM in PrEP uptake and adherence. The 
barriers for YMSM are of concern if they have limited financial capability to pay for 
PrEP and if the health care system limits PrEP provision. There is a need to 
systematically monitor HIV incidence, PrEP uptake, and retention disaggregated by 
age and race/ethnicity in different geographic settings. This should be coupled with 
well-designed MSM studies to ensure equitable access to PrEP.  
 A systematic review found that MSM PrEP users of continuous and episodic 
dosing regimens had high levels of medication adherence (Sidebottom et al., 2018), 
which was consistent with our findings. However, a limited evidence base suggested 
that substance users and those with mental health diagnoses may have higher levels 
of non-adherence. Substance use by MSM is particularly important, as gay and 
bisexual men are three times more likely to use illicit drugs than heterosexuals 
(Office for National Statistics, 2014). In particular, there are growing concerns about 
MSM who combine drugs with sex (Maxwell, Shahmanesh, & Gafos, 2019). 
Chemsex is the intentional use of psychoactive drugs to facilitate or enhance 
sex. A systematic review reported that up to 13% of MSM engaged in chemsex, 
which often results in high rates of CAI, multiple sex partners, partners of unknown 
HIV status, and injecting drug use (Maxwell et al., 2019). In a study of intended PrEP 
use, chemsex participants reported their drug use would negatively impact PrEP 
adherence and choice of dosing regimen would depend on frequency of drug use 
(Closson, Mitty, Malone, Mayer, & Mimiaga, 2018). The use of PrEP by substance 
users may be a viable HIV risk reduction strategy, but further research is required to 
examine PrEP use in substance users and the impact on adherence. Overall, further 
investigations are needed to explore PrEP medication adherence in specific MSM 
populations. 
To overcome barriers to adherence, it is important to examine what influences 
non-adherence. A systematic review of non-PrEP medication adherence in 
uninfected MSM reported that about 80% adhered to their medications, but barriers 
included forgetting, being away from home, and changes in daily routine (Liu et al., 
2014); their findings were consistent with our study, which found high adherence 
levels, but that daily logistics contributed to non-adherence.  
A specific influence for PrEP adherence was the user’s perception of stigma 
from community peers and health care providers. A systematic review from the 
United States reported that potential health care provider stigma related to HIV, 
PrEP, and same-sex behavior could keep high-risk individuals from starting PrEP 
(Pinto et al., 2018). Our findings were similar to Liu et al. (2014), who found that an 
established daily routine and pill boxes could promote adherence. However, limited 
research has examined facilitators of PrEP adherence in high-risk MSM.    
 
Strengths and Limitations              
Our review was strengthened by a clear search protocol and well-established 
frameworks to structure and analyze the wide array of evidence. Use of the ABC 
framework provided a clear and simple model to understand behavioral processes of 
MSM PrEP use. Our review was limited by a lack of clear sampling frameworks and 
the heterogenous nature of samples across studies. In addition, we only included 
studies that were fully published in English.  
 
Research Recommendations 
To better understand PrEP use by MSM in high-income countries, research in 
the following areas is recommended: (a) Examine prevalence estimates and patterns 
of PrEP use by age and race/ethnicity in different countries to ensure equitable 
access; (b) Examine changes in sexual behavior and diagnosis of STIs after PrEP 
initiation; and (c) Explore barriers and facilitators for PrEP uptake and adherence in 
high-risk MSM. As PrEP is an effective HIV risk reduction strategy and increasingly 
available in high-income countries, research in these areas would provide a 
foundation for evidence-based policy.  
 
Conclusion 
A minority of MSM in high-income countries use PrEP, but it appears to have 
increased in line with increasing availability. MSM who use PrEP were more often 
those who engaged in high-risk sexual behavior, but some users changed sexual 
behavior as a result of starting PrEP. MSM had high medication adherence levels 
but specific high-risk groups had a lower uptake, were less adherent, and might have 
been at higher risk of HIV acquisition. As PrEP is increasingly available, it is 
important to understand what facilitates PrEP uptake and supports adherence for 
MSM at higher risk of acquiring HIV. Finally, there is a specific need for research to 
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• PrEP users engage in high-risk sexual behaviors and PrEP initiation potentially 
means some users will risk compensate.  
• MSM have high PrEP adherence levels, but younger men, substance users, and 
those with a mental health diagnosis have higher non-adherence levels.  
• Barriers to PrEP uptake and adherence include stigma, side-effects, cost, daily 
logistics, and forgetting.  
• Facilitators that promote PrEP adherence include availability, daily routine, daily 
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Figure 1. Study selection process. 
 
 
Note. PrEP = pre-exposure prophylaxis. PRISMA flowchart from Moher, Liberati, 
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Figure 2. ABC summary of findings. 
 
Note. ABC = Antecedent, Behavior, Consequence; PrEP = pre-exposure 
prophylaxis; CAI = condomless anal intercourse; MSM = men who have sex with 
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